This article has been corrected to make clear that Genomic Health expects to make IVD products available in France and Germany in 2020.

NEW YORK (GenomeWeb) – Following a year of major milestones, Genomic Health CEO Kim Popovits said that the company expects to sustain and grow its momentum in 2019 with a focus on increasing adoption of its core breast cancer product in the US, pushing international expansions, and continuing to diversify its test menu.